Olr164 inhibitors are a class of chemical compounds specifically designed to target and inhibit the Olr164 receptor, which is a member of the olfactory receptor family within the G-protein coupled receptor (GPCR) superfamily. Olfactory receptors, including Olr164, are essential for the detection and processing of odorant molecules, playing a key role in the sensory perception of smells. The Olr164 receptor operates by binding to specific odorant ligands, initiating a cascade of intracellular signaling events that ultimately result in the activation of neural pathways responsible for conveying sensory information to the brain. This process is fundamental to the olfactory system's ability to discern and respond to a wide array of chemical stimuli in the environment. Olr164 inhibitors are developed to disrupt this process by binding to the receptor in a manner that prevents its natural ligands from activating it. This inhibition can occur through direct competition at the receptor's active site, where odorant molecules would typically bind, or by interacting with allosteric sites that induce conformational changes, thereby reducing the receptor's functional activity.
The development of Olr164 inhibitors involves a detailed and methodical approach to optimizing several key chemical properties, including binding affinity, selectivity, and stability. Researchers typically employ molecular modeling and docking simulations to predict how these inhibitors will interact with the Olr164 receptor, providing insights into the receptor's structure and identifying potential binding sites critical for effective inhibition. High-throughput screening of chemical libraries is another essential step in identifying lead compounds that exhibit promising inhibitory effects on Olr164. Once these lead compounds are identified, they undergo structure-activity relationship (SAR) studies to refine their chemical structures, enhancing their potency, selectivity, and overall stability while minimizing off-target effects on other receptors. This refinement process may involve modifying the core chemical scaffold or altering functional groups to improve the interaction with the receptor. Additionally, factors such as solubility, lipophilicity, and metabolic stability are carefully evaluated to ensure that these inhibitors can function effectively under physiological conditions. Through this meticulous development process, Olr164 inhibitors contribute to a deeper understanding of the molecular mechanisms underlying olfactory receptor function and advance the broader field of GPCR-mediated signal transduction, offering valuable insights into the complex processes that govern sensory perception and olfactory signaling.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | $167.00 $1353.00 | ||
Dual EGFR and VEGFR inhibitor, potentially affects pathways Olr164 may be involved in. | ||||||
Osimertinib | 1421373-65-0 | sc-507355 | 5 mg | $86.00 | ||
EGFR inhibitor, might disrupt signaling pathways relevant to Olr164. | ||||||
XL-184 free base | 849217-68-1 | sc-364657 sc-364657A | 5 mg 10 mg | $94.00 $208.00 | 1 | |
MET and VEGFR2 inhibitor, could impact angiogenesis and signaling related to Olr164. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
MEK inhibitor, potentially alters the MAPK/ERK pathway involving Olr164. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
JAK inhibitor, could modulate cytokine signaling pathways relevant to Olr164. | ||||||
Belinostat | 414864-00-9 | sc-269851 sc-269851A | 10 mg 100 mg | $156.00 $572.00 | ||
HDAC inhibitor, might alter gene expression and chromatin structure affecting Olr164. | ||||||
CH5424802 | 1256580-46-7 | sc-364461 sc-364461A | 5 mg 50 mg | $191.00 $902.00 | ||
ALK inhibitor, potentially disrupts pathways Olr164 is involved in. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
MEK inhibitor, might affect cell signaling pathways related to Olr164's function. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
CDK4/6 inhibitor, could impact cell cycle regulation pathways involving Olr164. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
mTOR inhibitor, may affect cell growth and survival pathways potentially involving Olr164. | ||||||